IL149617A0 - 4-pyrimidinyl-n-acyl-l-phenylalanines - Google Patents

4-pyrimidinyl-n-acyl-l-phenylalanines

Info

Publication number
IL149617A0
IL149617A0 IL14961700A IL14961700A IL149617A0 IL 149617 A0 IL149617 A0 IL 149617A0 IL 14961700 A IL14961700 A IL 14961700A IL 14961700 A IL14961700 A IL 14961700A IL 149617 A0 IL149617 A0 IL 149617A0
Authority
IL
Israel
Prior art keywords
phenylalanines
pyrimidinyl
acyl
Prior art date
Application number
IL14961700A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL149617A0 publication Critical patent/IL149617A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14961700A 1999-12-06 2000-11-28 4-pyrimidinyl-n-acyl-l-phenylalanines IL149617A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16908999P 1999-12-06 1999-12-06
PCT/EP2000/011884 WO2001042225A2 (fr) 1999-12-06 2000-11-28 4-pyrimidinyl-n-acyl-l-phenylalanines

Publications (1)

Publication Number Publication Date
IL149617A0 true IL149617A0 (en) 2002-11-10

Family

ID=22614222

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14961700A IL149617A0 (en) 1999-12-06 2000-11-28 4-pyrimidinyl-n-acyl-l-phenylalanines
IL149617A IL149617A (en) 1999-12-06 2002-05-13 4 – pyrimidinyl – N– noble – L– phenylalanines

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL149617A IL149617A (en) 1999-12-06 2002-05-13 4 – pyrimidinyl – N– noble – L– phenylalanines

Country Status (35)

Country Link
EP (1) EP1237878B1 (fr)
JP (1) JP3824935B2 (fr)
KR (1) KR100522344B1 (fr)
CN (1) CN1218943C (fr)
AR (1) AR034401A1 (fr)
AT (1) ATE357433T1 (fr)
AU (1) AU783348B2 (fr)
BR (1) BR0016195A (fr)
CA (1) CA2392570C (fr)
CO (1) CO5080772A1 (fr)
CY (1) CY1106626T1 (fr)
CZ (1) CZ303435B6 (fr)
DE (1) DE60034061T2 (fr)
DK (1) DK1237878T3 (fr)
EG (1) EG24361A (fr)
ES (1) ES2282162T3 (fr)
HK (1) HK1054384B (fr)
HR (1) HRP20020468B1 (fr)
HU (1) HU229105B1 (fr)
IL (2) IL149617A0 (fr)
JO (1) JO2283B1 (fr)
MA (1) MA26850A1 (fr)
MX (1) MXPA02005564A (fr)
MY (1) MY126972A (fr)
NO (1) NO322866B1 (fr)
NZ (1) NZ518828A (fr)
PE (1) PE20010961A1 (fr)
PL (1) PL207160B1 (fr)
PT (1) PT1237878E (fr)
RS (1) RS50371B (fr)
RU (1) RU2266901C2 (fr)
SI (1) SI1237878T1 (fr)
TW (1) TWI256387B (fr)
WO (1) WO2001042225A2 (fr)
ZA (1) ZA200203533B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
IL154350A0 (en) * 2000-08-18 2003-09-17 Ajinomoto Kk New phenylalanine derivatives
AR033765A1 (es) * 2001-05-22 2004-01-07 Syngenta Participations Ag Procedimiento para la preparacion de derivados 3-alquil-3h-isobenzofuran-1-ona 7-sustituidos.
WO2003053926A1 (fr) 2001-12-13 2003-07-03 Ajinomoto Co.,Inc. Nouveau derive de phenylalanine
EP2803667A1 (fr) 2003-12-22 2014-11-19 Ajinomoto Co., Inc. Dérivés de phenylalanine
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
CN101006097B (zh) * 2004-08-16 2012-07-11 默沙东公司 Vla-4拮抗剂
JP4784224B2 (ja) 2004-09-24 2011-10-05 味の素株式会社 糖鎖転移方法および糖鎖転移酵素
US20090137601A1 (en) * 2005-11-23 2009-05-28 Astrazeneca Ab L-Phenylalanine Derivatives
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
JP2009526032A (ja) * 2006-02-09 2009-07-16 アストラゼネカ アクチボラグ 化合物
CN101472900B (zh) * 2006-06-19 2011-07-27 东丽株式会社 多发性硬化症的治疗或预防药
US8178548B2 (en) 2007-09-17 2012-05-15 Abbott Laboratories Anti-infective agents and uses thereof
CN102746239B (zh) * 2007-09-17 2016-02-10 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
PT2368882E (pt) 2007-09-17 2014-11-27 Abbvie Bahamas Ltd Pirimidinas anti-infecciosas e seus usos
EP2382222B1 (fr) * 2008-12-22 2013-05-01 Icl-ip America Inc. Procédé à base de solvant miscible dans l'eau pour purifier un diphosphate
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
WO2012009699A2 (fr) 2010-07-16 2012-01-19 Abbott Laboratories Procédé de préparation de composés antiviraux
US8841487B2 (en) 2010-07-16 2014-09-23 Abbvie Inc. Phosphine ligands for catalytic reactions
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
WO2013110680A1 (fr) * 2012-01-27 2013-08-01 F. Hoffmann-La Roche Ag Conjugués d'antagonistes d'intégrine pour cibler des cellules exprimant le vla-4
US9447035B2 (en) * 2012-01-27 2016-09-20 Hoffmann-La Roche Inc. Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
CN106414413A (zh) * 2013-10-29 2017-02-15 Ea制药株式会社 磺酰胺衍生物及其药物用途
US10214522B2 (en) 2015-03-10 2019-02-26 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
AU2019373240B2 (en) 2018-10-30 2023-04-20 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CA3115830C (fr) 2018-10-30 2023-09-12 Gilead Sciences, Inc. Composes pour inhibition de l'integrine .alpha.4.beta.7
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CA3114240C (fr) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Derives d'imidazopyridine utilises en tant qu'inhibiteurs de l'integrine alpha4beta7
WO2021030438A1 (fr) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Composés pour l'inhibition de l'intégrine alpha 4 bêta 7

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2291778A1 (fr) * 1997-05-29 1998-12-03 Merck & Co., Inc. Composes d'amide heterocycliques utilises en tant qu'inhibiteurs de l'adhesion cellulaire
ATE318841T1 (de) * 1997-05-29 2006-03-15 Merck & Co Inc Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
PT1005446E (pt) * 1997-08-22 2004-06-30 Hoffmann La Roche Derivados de n-aroilfenilalanina
HU229362B1 (en) * 1997-08-22 2013-11-28 Hoffmann La Roche N-alkanoylphenylalanine derivatives
CN1231212C (zh) * 1999-01-22 2005-12-14 依兰制药公司 抑制vla－4介导的白细胞粘着的多环化合物

Also Published As

Publication number Publication date
NO20022633D0 (no) 2002-06-04
CN1407972A (zh) 2003-04-02
JP3824935B2 (ja) 2006-09-20
EG24361A (en) 2009-03-04
NO322866B1 (no) 2006-12-18
EP1237878A2 (fr) 2002-09-11
RS50371B (sr) 2009-11-10
EP1237878B1 (fr) 2007-03-21
YU40402A (sh) 2005-03-15
TWI256387B (en) 2006-06-11
JP2003516396A (ja) 2003-05-13
CN1218943C (zh) 2005-09-14
CZ303435B6 (cs) 2012-09-12
DK1237878T3 (da) 2007-07-30
AU2669601A (en) 2001-06-18
MA26850A1 (fr) 2004-12-20
PL357601A1 (en) 2004-07-26
PL207160B1 (pl) 2010-11-30
HU229105B1 (en) 2013-07-29
BR0016195A (pt) 2002-08-13
MXPA02005564A (es) 2002-09-02
JO2283B1 (en) 2005-09-12
IL149617A (en) 2007-10-31
KR20020063906A (ko) 2002-08-05
DE60034061T2 (de) 2007-12-13
PE20010961A1 (es) 2001-09-26
HUP0204081A2 (en) 2003-05-28
DE60034061D1 (de) 2007-05-03
NZ518828A (en) 2004-03-26
WO2001042225A3 (fr) 2002-02-21
RU2002117422A (ru) 2004-03-10
CZ20022351A3 (cs) 2003-04-16
HUP0204081A3 (en) 2003-07-28
HRP20020468B1 (en) 2009-02-28
NO20022633L (no) 2002-06-04
ATE357433T1 (de) 2007-04-15
KR100522344B1 (ko) 2005-10-20
ZA200203533B (en) 2003-08-04
AU783348B2 (en) 2005-10-20
SI1237878T1 (sl) 2007-08-31
AR034401A1 (es) 2004-02-25
HK1054384A1 (en) 2003-11-28
HRP20020468A2 (en) 2004-04-30
RU2266901C2 (ru) 2005-12-27
WO2001042225A8 (fr) 2002-06-06
ES2282162T3 (es) 2007-10-16
CA2392570A1 (fr) 2001-06-14
MY126972A (en) 2006-11-30
HK1054384B (zh) 2005-12-09
PT1237878E (pt) 2007-06-18
WO2001042225A2 (fr) 2001-06-14
CY1106626T1 (el) 2012-01-25
CO5080772A1 (es) 2001-09-25
CA2392570C (fr) 2010-05-11

Similar Documents

Publication Publication Date Title
DE60018571D1 (en) Hernienprothese
DE60033307D1 (en) Heteroalkylamino-substituierte bicyclische stickstoffheterocyclen
DE60008112D1 (en) Respiratorisches syncytialvirus replikation inhibitoren
DE60037335D1 (en) Polymerizationsverfahren
DE60008382D1 (en) Respiratorisches syncytialvirus replikation inhibitoren
DE50002490D1 (en) Polyester-polyetherblockcopolymere
HRP20020468A2 (en) 4-pyrimidinyl-n-acyl-l-phenylalanines
DE60018288D1 (en) Polyphenylensulfidlegierungszusammensetzung
DE60027722D1 (en) Aspartyl-protease inhibitoren
DE50002614D1 (en) Sigma-delta-modulator
DE60034237D1 (en) Ferrofluidabdichtung
DE60007505D1 (en) Propargyletherderivate
DE60028360D1 (en) Ptk-chipthermistor
DE60036727D1 (en) Differentialverstärker
DE50000137D1 (en) Spirofluorenopyrane
DE60011809D1 (en) Oxcarbazepinsuspension
DE59909975D1 (en) Testleck
DE10081629D2 (en) Seilzugbefestigung
DE50009469D1 (en) Common-rail-injektor
DE50010757D1 (en) Stilbenaufheller
DE60044740D1 (en) Hochtemperatur-differentialrefraktometer
DE60026282D1 (en) Photovervielfacherröhre
DE60001313D1 (en) Imidazodiazepinderivate
DE60037536D1 (en) Polypeptidhormon phosphatonin
DE50012999D1 (en) Stirnwandisolation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed